The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids

Shree Bose; Xiling Shen

doi:10.1016/j.stem.2023.12.010

The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids

Cell Stem Cell. 2024 Jan 4;31(1):1-2. doi: 10.1016/j.stem.2023.12.010.

Authors

Shree Bose¹, Xiling Shen²

Affiliations

¹ Department of Internal Medicine, University of Chicago, Chicago, IL, USA.
² Terasaki Institute for Biomedical Innovation, Los Angeles, CA, USA. Electronic address: [email protected].

PMID: 38181746
DOI: 10.1016/j.stem.2023.12.010

Abstract

Using an isogenic organoid platform to model pancreatic cancer, Duan et al. establish an important link between mutant KRAS and cholesterol metabolism and identify perhexiline maleate as a possible therapeutic to target this relationship.

Publication types

News
Comment

MeSH terms

Humans
Lipid Metabolism
Metabolic Reprogramming*
Organoids
Pancreatic Neoplasms*
Proto-Oncogene Proteins p21(ras) / genetics

Substances

KRAS protein, human
Proto-Oncogene Proteins p21(ras)